Graph AI
An AI-native pharmacovigilance platform that helps pharmaceutical safety teams process adverse-event cases, connect evidence and prepare regulatory reporting while keeping experts in control of safety decisions.
$13.3MSeries A
LeadIP
Insight Partners
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Healthtech · Jan 1, 2026
Insight Partners invests in software companies from early stages through growth and later-stage expansion, with an operating team focused on the work of scaling a software business.
Its Onsite team provides specialist support in hiring, marketing, product, acquisitions and international expansion. Founders can work with operators on questions such as building a sales organisation, recruiting leadership and improving growth efficiency.
Insight’s model is particularly relevant when a company is turning product-market fit into a repeatable business. Its investment platform can address both the capital needed for expansion and the organisational changes that accompany it.
Sources
- Rounds participated in
- 5
- Confirmed lead rounds
- 1 3 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $181.3M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionInspiren
Inspiren equips senior-living communities with connected devices and software that help staff prevent falls and coordinate resident care.
$70MSeries C
ParticipantTytoCare
AI-first clinical enablement company and developer of remote physical examination technology featuring FDA-cleared medical devices
>$25MGrowth
Role not disclosedIterative Health
Develops technology and services for clinical research.
$77MSeries C
Role not disclosedPasito
Builds AI-native workspace for group health life and retirement benefits operations
$21MSeries A
Role not disclosed